Yellox

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
15-09-2022
Produktens egenskaper Produktens egenskaper (SPC)
15-09-2022

Aktiva substanser:

bromfenac sodium sesquihydrate

Tillgänglig från:

Bausch + Lomb Ireland Limited

ATC-kod:

S01BC11

INN (International namn):

bromfenac

Terapeutisk grupp:

Ophthalmologicals

Terapiområde:

Pain, Postoperative; Ophthalmologic Surgical Procedures

Terapeutiska indikationer:

Treatment of postoperative ocular inflammation following cataract extraction in adults.

Produktsammanfattning:

Revision: 11

Bemyndigande status:

Authorised

Tillstånd datum:

2011-05-18

Bipacksedel

                                16
B. PACKAGE LEAFLET
17
PACKAGE LEAFLET: INFORMATION FOR THE USER
YELLOX 0.9 MG/ML EYE DROPS, SOLUTION
Bromfenac
_ _
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
_ _
WHAT IS IN THIS LEAFLET:
1.
What Yellox is and what it is used for
2.
What you need to know before you use Yellox
3.
How to use Yellox
4.
Possible side effects
5.
How to store Yellox
6.
Contents of the pack and other information
_ _
_ _
1.
WHAT YELLOX IS AND WHAT IT IS USED FOR
Yellox contains bromfenac and belongs to a group of medicines called
non-steroidal anti-
inflammatory drugs (NSAIDs). It works by blocking certain substances
involved in causing
inflammation.
Yellox is used to reduce eye inflammation following cataract surgery
in adults.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE YELLOX
DO NOT USE YELLOX
-
if you are allergic to bromfenac or to any of the other ingredients of
this medicine (listed in
section 6).
-
if you have experienced asthma, skin allergy or intense inflammation
in your nose when using
other NSAIDs. Examples of NSAIDs are: acetylsalicylic acid, ibuprofen,
ketoprofen,
diclofenac.
WARNING AND PRECAUTIONS
Talk to your doctor or pharmacist before using this medicine
-
if you are using topical steroids (e.g. cortisone), as this may cause
unwanted side effects.
-
if you have bleeding problems (e.g. haemophilia) or have had them in
the past, or you are taking
other medicines which may prolong bleeding time (e.g. warfarin,
clopidogrel, acetylsalicylic
acid).
-
if you have eye problems (e.g. dry eye syndrome, corneal problems).
-
if you have diabe
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
_ _
_ _
2
1.
NAME OF THE MEDICINAL PRODUCT
Yellox 0.9 mg/ml eye drops solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 ml of solution contains 0.9 mg bromfenac (as sodium sesquihydrate).
One drop contains approximately 33 micrograms bromfenac.
Excipient(s) with known effect:
Each ml of solution contains 50 micrograms of benzalkonium chloride.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Eye drops, solution.
Clear yellow solution.
pH: 8.1-8.5; osmolality: 270-330 mOsmol/kg
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Yellox is indicated in adults for the treatment of postoperative
ocular inflammation following cataract
extraction .
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Use in adults, including the elderly _
The dose is one drop of Yellox in the affected eye(s) twice daily,
beginning the next day after cataract
surgery and continuing through the first 2 weeks of the postoperative
period.
The treatment should not exceed 2 weeks as safety data beyond this is
not available.
Hepatic and renal impairment
Yellox has not been studied in patients with hepatic disease or renal
impairment.
Paediatric population
The safety and efficacy of bromfenac in paediatric patients has not
been established. No data are
available.
Method of administration
For ocular use.
If more than one topical ophtalmic medicinal product is being used,
each one should be administered
at least 5 minutes apart.
To prevent contamination of the dropper-tip and solution, care must be
taken not to touch the eyelids,
surrounding areas or other surfaces with the dropper-tip of the bottle
3
4.3
CONTRAINDICATIONS
Hypersensitivity to bromfenac or to any of the excipients listed in
section 6.1, or to other non-
steroidal anti-inflammatory medicinal products (NSAIDs).
Yellox is contraindicated in patients in whom attacks of asthma,
urticaria or acute rhinitis are
precipitated by acetylsalicylic acid or by other medicinal products
with prostaglandin synthetase
inhibit
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 15-09-2022
Produktens egenskaper Produktens egenskaper bulgariska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 17-11-2017
Bipacksedel Bipacksedel spanska 15-09-2022
Produktens egenskaper Produktens egenskaper spanska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 17-11-2017
Bipacksedel Bipacksedel tjeckiska 15-09-2022
Produktens egenskaper Produktens egenskaper tjeckiska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 17-11-2017
Bipacksedel Bipacksedel danska 15-09-2022
Produktens egenskaper Produktens egenskaper danska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 17-11-2017
Bipacksedel Bipacksedel tyska 15-09-2022
Produktens egenskaper Produktens egenskaper tyska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 17-11-2017
Bipacksedel Bipacksedel estniska 15-09-2022
Produktens egenskaper Produktens egenskaper estniska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 17-11-2017
Bipacksedel Bipacksedel grekiska 15-09-2022
Produktens egenskaper Produktens egenskaper grekiska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 17-11-2017
Bipacksedel Bipacksedel franska 15-09-2022
Produktens egenskaper Produktens egenskaper franska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 17-11-2017
Bipacksedel Bipacksedel italienska 15-09-2022
Produktens egenskaper Produktens egenskaper italienska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 17-11-2017
Bipacksedel Bipacksedel lettiska 15-09-2022
Produktens egenskaper Produktens egenskaper lettiska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 17-11-2017
Bipacksedel Bipacksedel litauiska 15-09-2022
Produktens egenskaper Produktens egenskaper litauiska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 17-11-2017
Bipacksedel Bipacksedel ungerska 15-09-2022
Produktens egenskaper Produktens egenskaper ungerska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 17-11-2017
Bipacksedel Bipacksedel maltesiska 15-09-2022
Produktens egenskaper Produktens egenskaper maltesiska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 17-11-2017
Bipacksedel Bipacksedel nederländska 15-09-2022
Produktens egenskaper Produktens egenskaper nederländska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 17-11-2017
Bipacksedel Bipacksedel polska 15-09-2022
Produktens egenskaper Produktens egenskaper polska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 17-11-2017
Bipacksedel Bipacksedel portugisiska 15-09-2022
Produktens egenskaper Produktens egenskaper portugisiska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 17-11-2017
Bipacksedel Bipacksedel rumänska 15-09-2022
Produktens egenskaper Produktens egenskaper rumänska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 17-11-2017
Bipacksedel Bipacksedel slovakiska 15-09-2022
Produktens egenskaper Produktens egenskaper slovakiska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 17-11-2017
Bipacksedel Bipacksedel slovenska 15-09-2022
Produktens egenskaper Produktens egenskaper slovenska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 17-11-2017
Bipacksedel Bipacksedel finska 15-09-2022
Produktens egenskaper Produktens egenskaper finska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 17-11-2017
Bipacksedel Bipacksedel svenska 15-09-2022
Produktens egenskaper Produktens egenskaper svenska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 17-11-2017
Bipacksedel Bipacksedel norska 15-09-2022
Produktens egenskaper Produktens egenskaper norska 15-09-2022
Bipacksedel Bipacksedel isländska 15-09-2022
Produktens egenskaper Produktens egenskaper isländska 15-09-2022
Bipacksedel Bipacksedel kroatiska 15-09-2022
Produktens egenskaper Produktens egenskaper kroatiska 15-09-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport kroatiska 17-11-2017

Sök varningar relaterade till denna produkt

Visa dokumenthistorik